Department of Dermatology, University of Regensburg, Regensburg, Germany.
Anticancer Res. 2010 Oct;30(10):4017-23.
BACKGROUND/AIM: Beyond their primary field of application some well-established drugs exhibit antitumour effects in a variety of cancers. The aim of this study was to investigate the effects of the COX2 inhibitor celecoxib and the mTOR antagonist rapamycin on angiosarcoma cell lines.
Cell proliferation was measured in ASM, ISOS 1 and ISO HAS angiosarcoma cell lines with the BrdU assay.
In all angiosarcoma cell lines, celecoxib as well as rapamycin inhibited cell growth in a dose-dependent manner. In ASM and ISOS 1, but not in ISO HAS angiosarcoma cells, additive growth inhibitory effects were detected by combining both agents.
Our results indicate that angiosarcoma cell proliferation can be inhibited by subtoxic doses of rapamycin and celecoxib. Due to their direct and stroma-mediated anticancer activities, mTOR antagonists and COX2 inhibitors represent very promising drugs in the palliative treatment of angiosarcoma.
背景/目的：一些成熟的药物除了主要应用领域之外，在多种癌症中还表现出抗肿瘤作用。本研究旨在研究 COX2 抑制剂塞来昔布和 mTOR 拮抗剂雷帕霉素对血管肉瘤细胞系的影响。
采用 BrdU 法检测 COX2 抑制剂塞来昔布和 mTOR 拮抗剂雷帕霉素对 ASM、ISOS 1 和 ISO HAS 血管肉瘤细胞系的细胞增殖的影响。
在所有血管肉瘤细胞系中，塞来昔布和雷帕霉素均呈剂量依赖性抑制细胞生长。在 ASM 和 ISOS 1 中，但在 ISO HAS 血管肉瘤细胞中，联合使用两种药物可检测到相加的生长抑制作用。
我们的结果表明，雷帕霉素和塞来昔布的亚毒性剂量可抑制血管肉瘤细胞的增殖。由于其直接和基质介导的抗癌活性，mTOR 拮抗剂和 COX2 抑制剂在血管肉瘤的姑息治疗中是非常有前途的药物。
